HIV & AIDS: Theme A Symposium - Prevention
Tracks
1
| Monday, November 6, 2017 |
| 2:00 PM - 3:30 PM |
| Nicholls Theatrette |
Details
This session will cover the full spectrum of prevention strategies including PREP, microbiome/microbicides, passive antibody transfer and vaccine strategies and immune responses required for sterilizing immunity.
Speaker
Professor Gilda Tachedjian
Head, Life Sciences Discipline
Burnet Institute
Vaginal Microbiome and HIV Susceptibility
2:00 PM - 2:15 PMBiography
Prof Gilda Tachedjian (PhD) is a NHMRC Senior Research Fellow and Heads the Life Sciences Discipline and Retroviral Biology and Antivirals Laboratory at the Burnet Institute. Her research focuses on identifying and developing antiviral strategies to prevent and control HIV.
Associate Professor Charani Ranasinghe
Associate Professor and Group Leader
The Australian National University
Professor Eric Gowans
Senior Research Fellow
University Of Adelaide
Miss Samantha Davis
PhD candidate
The University of Melbourne
Fcγ Receptor Binding Breadth Of RV144 Antibodies
2:45 PM - 3:00 PMBiography
Amy completed her PhD in 2011, then conducted a postdoc at the Ragon Institute of MGH, MIT and Harvard, Boston. She returned to the University of Melbourne, working with Prof Stephen Kent, in 2015. She has published over 25 peer-reviewed manuscripts and is Chair of the Melbourne HIV Exchange Network.
Dr Matthew Parsons
Postdoc
University Of Melbourne
Professor Damian Purcell
Professor of Virology and Theme Leader for Viral Infectious Diseases
Uni Melbourne, Doherty Institute
HIV vaccine-induced protective antibodies: lessons from the sacred cow
3:15 PM - 3:30 PMBiography
Dr. Damian Purcell is a Professor in Virology and head of the molecular virology laboratory in the Department of Microbiology and Immunology at the University of Melbourne. He is Viral Infectious Diseases theme leader and GVN co-director at the Peter Doherty Institute, and on the executive committee of AVS, and ACH2. His research is in HIV and HTLV: gene expression, preventive vaccines, and antiviral and curative therapeutics.
